Overview

A Study to Evaluate the Bioavailability of Risankizumab in Pre-filled Syringe or Auto-injector in Healthy Adult Participants

Status:
Completed

Trial end date:
2019-11-11

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate the bioavailability of risankizumab new formulation in prefilled syringe (PFS) relative to the 90 mg/mL formulation in PFS in healthy volunteers. The study will also evaluate the bioavailability of risankizumab new formulation in auto-injector (AI) relative to PFS in healthy volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

AbbVie

Treatments:

Antibodies, Monoclonal